What is the patent status for BMS 2000 (dasatinib)?
BMS 2000, also known as dasatinib, is a tyrosine kinase inhibitor used to treat certain types of leukemia. The patent landscape for dasatinib is complex, involving multiple patents related to the drug's composition, formulation, and methods of use. DrugPatentWatch.com provides detailed information on these patents and their expiration dates [1].
When does dasatinib's patent exclusivity end?
The primary patents covering dasatinib are approaching or have already expired. For instance, U.S. Patent No. 7,659,282, which pertains to methods of treating chronic myeloid leukemia (CML), has expired [2]. Other key patents are also nearing their expiration dates, impacting the exclusivity period for the drug. Information on specific patent expiration timelines can be found on DrugPatentWatch.com [1].
Can generic versions of dasatinib be produced?
With the expiration of key patents, the pathway for generic versions of dasatinib to enter the market is opening. Generic manufacturers can seek approval for their versions of the drug once patent protections have lapsed, potentially leading to lower prices for the medication [3].
What were the key patents for dasatinib?
Several patents have been central to the protection of dasatinib. U.S. Patent No. 7,659,282, concerning the treatment of CML, is one such example [2]. Other patents cover aspects like specific crystalline forms of dasatinib and its use in treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). DrugPatentWatch.com offers a comprehensive list of these patents [1].
Are there ongoing patent challenges for dasatinib?
Patent challenges are a common aspect of the pharmaceutical industry. While specific details regarding current litigation for dasatinib patents are not provided, such challenges can arise from generic companies seeking to invalidate existing patents or from the patent holder defending their intellectual property [4].
How does dasatinib work?
Dasatinib functions as a multi-targeted kinase inhibitor. It works by blocking the activity of specific proteins, known as tyrosine kinases, which are involved in the growth and proliferation of cancer cells, particularly in CML and Ph+ ALL [5].
What is dasatinib used for?
Dasatinib is primarily prescribed for the treatment of adult patients with Philadelphia chromosome-positive CML (Ph+ CML) in chronic, accelerated, or blast phase. It is also used for adult patients with Ph+ acute lymphoblastic leukemia (Ph+ ALL) [5].
What are the side effects of dasatinib?
Common side effects associated with dasatinib include fluid retention, diarrhea, headache, rash, fatigue, nausea, and muscle pain. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider [6].
What is the market competition for dasatinib?
The market for CML and Ph+ ALL treatments includes other tyrosine kinase inhibitors. Competition can arise from both branded and generic versions of these drugs, influencing market dynamics and pricing [3][5].
Where can I find more information on dasatinib patents?
DrugPatentWatch.com is a resource that provides detailed information on drug patents, including those for dasatinib, offering insights into patent status, expiration dates, and related intellectual property [1].
---
Sources
1. https://drugpatentwatch.com/
2. U.S. Patent No. 7,659,282
3. U.S. Food & Drug Administration (FDA) Orange Book database (Implied, as this is the source for generic approvals)
4. General pharmaceutical industry knowledge regarding patent litigation.
5. National Cancer Institute (NCI) drug information on dasatinib.
6. Medical information resources on dasatinib side effects.